Diabetes Medication to Reduce Age-Related Eye Disorders Beyond Glucose Control-Reply

Joëlle E Vergroesen^{1

2}, Caroline C W Klaver^{1

2

3

4

5}, Wishal D Ramdas¹

Affiliations

¹ Department of Ophthalmology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
² Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
³ EyeNED Reading Center, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
⁴ Department of Ophthalmology, Radboud University Medical Center, Nijmegen, the Netherlands.
⁵ Institute of Molecular and Clinical Ophthalmology, University of Basel, Basel, Switzerland.

Comment

Joëlle E Vergroesen et al. JAMA Ophthalmol. 2023.

. 2023 Apr 1;141(4):405-406.

doi: 10.1001/jamaophthalmol.2022.6317.

Joëlle E Vergroesen^{1

2}, Caroline C W Klaver^{1

2

3

4

5}, Wishal D Ramdas¹

¹ Department of Ophthalmology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
² Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
³ EyeNED Reading Center, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
⁴ Department of Ophthalmology, Radboud University Medical Center, Nijmegen, the Netherlands.
⁵ Institute of Molecular and Clinical Ophthalmology, University of Basel, Basel, Switzerland.

No abstract available

Comment on

Association of Diabetes Medication With Open-Angle Glaucoma, Age-Related Macular Degeneration, and Cataract in the Rotterdam Study.
Vergroesen JE, Thee EF, Ahmadizar F, van Duijn CM, Stricker BH, Kavousi M, Klaver CCW, Ramdas WD. Vergroesen JE, et al. JAMA Ophthalmol. 2022 Jul 1;140(7):674-681. doi: 10.1001/jamaophthalmol.2022.1435. JAMA Ophthalmol. 2022. PMID: 35587864 Free PMC article.
Diabetes Medication to Reduce Age-Related Eye Disorders Beyond Glucose Control.
Feldman-Billard S. Feldman-Billard S. JAMA Ophthalmol. 2023 Apr 1;141(4):405. doi: 10.1001/jamaophthalmol.2022.6320. JAMA Ophthalmol. 2023. PMID: 36795384 No abstract available.